This is a Single-center, Two-sequence, Open-label, Two-cycle Drug-drug Interaction (DDI) Study in Healthy Subjects. To Evaluate the Effects of Itraconazole Capsules, a Strong Inhibitor of CYP3A4, and Rifampicin Capsules, a Strong Inducer, on the Pharmacokinetics of TY-9591 Tablets After a Single Oral Dose
Latest Information Update: 03 Jan 2025
At a glance
- Drugs TY 9591 (Primary) ; Itraconazole; Rifampicin
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors TYK Medicine
Most Recent Events
- 27 Dec 2024 Status changed from recruiting to completed.
- 16 Feb 2024 New trial record